The present invention relates to a process for preparing Linagliptin by purifying the intermediate compounds converting the purified intermediates into Linagliptin.
The present invention also relates to the preparation of an amorphous Linagliptin.
The present invention discloses an improved method for preparing an important intermediate of linagliptin.
Further the present application relates to the use of the linagliptin novel polymorphs for the preparation of a medicament, and pharmaceutical compositions comprising an effective amount of the crystalline linagliptin polymorphs.
The present invention relates to an amorphous form of linagliptin and processes for the preparation thereof.
The present invention provides an improved process for the preparation of linagliptin and an intermediate thereof.
Trajentamet contains two different active substances, linagliptin and metformin.
To date, three new treatments for diabetes have been launched by the alliance: Trajenta® (linagliptin), Jardiance® (empagliflozin), and Jentadueto® (linagliptin/metformin HCI).
Empagliflozin in patients inadequately controlled with metformin and linagliptin
When already being treated with the free combination of empagliflozin and linagliptin SMC
DPP-4 inhibitors should be dose adjusted, except for Linagliptin.
The present invention relates to a novel polymorph of Linagliptin benzoate and to methods for its preparation.
Further aspects of the present invention relates to process for the preparation of Linagliptin key intermediate, having purity more than 98.0 %.
Therefore, sitagliptin is not an inhibitor of OCT-mediated transport.
The recommended dose of this medication is determined by your current dose of empagliflozin or linagliptin.
In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel polymorph of Linagliptin benzoate.
Both empagliflozin and linagliptin belong to the class of medications called oral hypoglycemics.
Incretin-based therapies: sitagliptin, saxagliptin, linagliptin, alogliptin (alone or in combination with metformin) and exenatide.
The recommended starting dose of Janumet depends on your current dose of metformin or sitagliptin.
The present invention relates to a pharmaceutical composition comprising linagliptin and one or more pharmaceutically acceptable excipients, wherein said composition is free of mannitol.
Requêtes fréquentes français :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Requêtes fréquentes anglais :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Traduction Translation Traducción Übersetzung Tradução Traduzione Traducere Vertaling Tłumaczenie Mετάφραση Oversættelse Översättning Käännös Aistriúchán Traduzzjoni Prevajanje Vertimas Tõlge Preklad Fordítás Tulkojumi Превод Překlad Prijevod 翻訳 번역 翻译 Перевод